Form 4: Trevi Therapeutics Executive Granted Stock Options
SEC Form 4 Filing
Thomas Sciascia, Chief Scientific Officer of Trevi Therapeutics, was granted stock options for 116,000 shares on February 18, 2025.
Summary
- Thomas Sciascia, the Chief Scientific Officer of Trevi Therapeutics, Inc., was granted stock options.
- The transaction occurred on February 18, 2025.
- The stock options grant is for 116,000 shares of common stock.
- The exercise price of the options is $4.22 per share.
- The options vest as to 25% on February 18, 2026, and the remaining 75% vest in equal monthly installments through February 18, 2029.
- The options expire on February 17, 2035.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for management.
Positives
- The granting of stock options to the Chief Scientific Officer aligns his interests with those of the shareholders.
- The vesting schedule incentivizes long-term commitment and performance.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the options.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize key executives and align their interests with those of shareholders. This grant is typical for a company of Trevi Therapeutics' size and stage.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the pharmaceutical and biotechnology industries.
- Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options to incentivize their executives.
- The vesting schedule and exercise price are within typical ranges for similar grants in the industry, but without further information on the executive's total compensation package, it's difficult to make a precise comparison.
Stakeholder Impact
- Shareholders may view the option grant as a positive incentive for the Chief Scientific Officer.
- Employees may see this as a sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 02/18/2025 | Date of stock option grant |
| 02/18/2026 | First vesting date (25% of shares) |
| 02/18/2029 | End of monthly vesting installments |
| 02/17/2035 | Expiration date of the stock options |
| 02/20/2025 | Date of Form 4 signature |
Keywords
stock options, Trevi Therapeutics, TRVI, Chief Scientific Officer, Sciascia, executive compensation, Form 4, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.